| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | AKAP12 |
| Uniprot No | Q02952 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AKAP12重组蛋白的3篇参考文献的简要总结：
1. **"AKAP12 regulates tumorigenic potential of triple-negative breast cancer through ubiquitination of PP2A"**
- **作者**: Kim et al.
- **摘要**: 研究利用AKAP12重组蛋白揭示其通过泛素化修饰PP2A抑制三阴性乳腺癌的恶性表型，证实其通过调控细胞周期和凋亡通路发挥抑癌作用。
2. **"AKAP12 suppresses tumor metastasis by modulating Wnt/β-catenin signaling in hepatocellular carcinoma"**
- **作者**: Wang et al.
- **摘要**: 通过大肠杆菌表达系统获得AKAP12重组蛋白，发现其抑制肝癌细胞迁移和侵袭，机制涉及阻断Wnt/β-catenin信号通路的激活。
3. **"Structural and functional analysis of AKAP12 interactions with protein kinase A"**
- **作者**: Jones et al.
- **摘要**: 利用重组AKAP12蛋白进行体外结合实验，解析其与PKA的相互作用结构域，阐明其在细胞极性调控中的分子机制。
4. **"AKAP12 modulates endothelial cell angiogenesis via VEGFR2 signaling"**
- **作者**: Lee et al.
- **摘要**: 研究通过哺乳动物细胞表达的AKAP12重组蛋白，证明其抑制血管内皮生长因子(VEGF)介导的血管生成，为抗血管治疗提供新靶点。
这些文献聚焦于AKAP12重组蛋白在肿瘤抑制、信号通路调控及结构功能分析中的应用。
AKAP12. also known as A-kinase anchoring protein 12 or scaffolding protein SSeCKS, is a multifunctional regulatory protein that plays a critical role in organizing intracellular signaling networks. As a member of the AKAP family, it acts as a scaffold to spatially and temporally coordinate the activity of protein kinases, phosphatases, and other signaling molecules. The native AKAP12 protein contains three conserved domains that bind key signaling components: protein kinase A (PKA), protein kinase C (PKC), and β-arrestin, enabling cross-talk between cAMP, calcium, and G-protein-coupled receptor pathways.
Recombinant AKAP12 proteins are engineered to study its biological functions and therapeutic potential. These recombinant versions, often expressed in bacterial or mammalian systems, retain critical phosphorylation sites (e.g., Ser1033 and Ser1063) that modulate its scaffolding activity and interactions with cytoskeletal components. Researchers utilize recombinant AKAP12 to investigate its role in cell cycle regulation, particularly at G1/S and G2/M checkpoints, where it controls cyclin D1 expression and restricts mitotic progression.
The protein's tumor-suppressive properties have garnered significant interest. Recombinant AKAP12 has been shown to inhibit cancer metastasis by suppressing VEGF-mediated angiogenesis and integrin-dependent cell migration through cytoskeletal remodeling. Its ability to sequester oncogenic signaling molecules like PKC and Ras makes it a potential therapeutic target. In neurodegenerative research, recombinant AKAP12 helps elucidate its neuroprotective effects through β-amyloid regulation.
Current applications include using recombinant AKAP12 as a tool to map signaling complexes, develop kinase activity assays, and screen drugs targeting scaffold-dependent pathways. Challenges remain in maintaining post-translational modifications critical for its membrane-associated functions during recombinant production. Ongoing studies focus on optimizing expression systems to preserve its native conformation for structural and functional analyses.
×
